Tremfya

Tremfya

guselkumab

Manufacturer:

Janssen

Distributor:

DCH Auriga - Healthcare
/
Four Star
Concise Prescribing Info
Contents
Guselkumab
Indications/Uses
Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
Dosage/Direction for Use
SC 100 mg at wk 0 & 4, followed by maintenance dose every 8 wk.
Contraindications
Serious hypersensitivity. Clinically important active infections (eg, active TB).
Special Precautions
Discontinue use in case of serious hypersensitivity reactions. Increased risk of infection. Evaluate for TB prior to treatment initiation. Monitor for signs & symptoms of active TB during & after treatment. Concurrent use w/ live vaccines. Withhold treatment for at least 12 wk after last dose prior to live viral or bacterial vaccination; treatment can be resumed 2 wk after vaccination. Women of childbearing potential should use effective methods of contraception during & for at least 12 wk after treatment. Pregnancy & lactation. Elderly ≥65 yr. Childn & adolescent <18 yr.
Adverse Reactions
Upper resp infection. Gastroenteritis, herpes simplex & tinea infections; headache; diarrhoea; urticaria; arthralgia; inj site erythema.
Drug Interactions
Concomitant use w/ immunosuppresants (eg, biologics) or phototherapy.
ATC Classification
L04AC16 - guselkumab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.
Presentation/Packing
Form
Tremfya soln for inj 100 mg/mL
Packing/Price
1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in